PubRank

Jeffrey A Medin

Author PubWeight™ 56.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res 2009 2.79
2 The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 2011 2.04
3 Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther 2007 1.91
4 Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006 1.39
5 Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci U S A 2004 1.25
6 Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc Natl Acad Sci U S A 2006 1.23
7 Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics 2012 1.08
8 Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Mol Cancer Ther 2008 1.06
9 Isolation of cell surface proteins for mass spectrometry-based proteomics. Expert Rev Proteomics 2010 1.05
10 Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model. PLoS One 2011 1.02
11 Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy 2011 1.01
12 Lack of susceptibility of cells from patients with Fabry disease to productive infection with R5 human immunodeficiency virus. AIDS 2005 1.00
13 A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. J Nucl Med 2010 1.00
14 Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res 2012 0.97
15 Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling: a regulator of bone marrow-derived dendritic cells. Circulation 2009 0.97
16 In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res 2010 0.97
17 H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer 2006 0.96
18 On-tissue localization of ceramides and other sphingolipids by MALDI mass spectrometry imaging. Anal Chem 2014 0.94
19 Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med 2013 0.94
20 Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J 2006 0.94
21 Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica 2012 0.92
22 Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. Circ J 2006 0.92
23 IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy. J Cell Mol Med 2009 0.91
24 Spontaneous fibroblast-derived pericyte recruitment in a human tissue-engineered angiogenesis model in vitro. J Cell Physiol 2012 0.89
25 Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates. Hum Gene Ther 2011 0.88
26 Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease. J Cardiol 2010 0.87
27 Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Expert Rev Vaccines 2006 0.86
28 Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther 2008 0.86
29 Identification of novel mutations in the α-galactosidase A gene in patients with Fabry disease: pitfalls of mutation analyses in patients with low α-galactosidase A activity. J Cardiol 2011 0.85
30 A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007 0.85
31 A novel tissue-engineered approach to problems of the postpneumonectomy space. Ann Thorac Surg 2011 0.83
32 Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. Mol Ther 2012 0.83
33 Human adipose-derived mesenchymal stem cells engineered to secrete IL-10 inhibit APC function and limit CNS autoimmunity. Brain Behav Immun 2013 0.83
34 In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Mol Genet Metab 2008 0.83
35 Relaxin-3 and receptors in the human and rhesus brain and reproductive tissues. Regul Pept 2010 0.82
36 The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB J 2003 0.82
37 Lentiviral vectors for gene therapy of heart disease. J Cardiol 2007 0.82
38 Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming. Cancer Res 2010 0.81
39 Local long-term expression of lentivirally delivered IL-10 in the lung attenuates obliteration of intrapulmonary allograft airways. Hum Gene Ther 2011 0.81
40 Localized interleukin-12 delivery for immunotherapy of solid tumours. J Cell Mol Med 2013 0.81
41 Harnessing autophagy for cell fate control gene therapy. Autophagy 2013 0.81
42 Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Front Biosci 2008 0.81
43 Lentiviral vectors in cancer immunotherapy. Immunotherapy 2015 0.80
44 Direct injection of kit ligand-2 lentivirus improves cardiac repair and rescues mice post-myocardial infarction. Mol Ther 2008 0.80
45 Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Mol Cancer Ther 2009 0.80
46 Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice. Mol Ther 2012 0.80
47 Vascular endothelial growth factor broadens lentivector distribution in the heart after neonatal injection. J Cardiol 2009 0.79
48 Multiple reduced-intensity conditioning regimens facilitate correction of Fabry mice after transplantation of transduced cells. Mol Ther 2007 0.79
49 Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity. Mol Ther 2007 0.79
50 Specific pharmacological dimerization of KDR in lentivirally transduced human hematopoietic cells activates anti-apoptotic and proliferative mechanisms. FASEB J 2005 0.79
51 Neonatal transfer of membrane-bound stem cell factor improves survival and heart function in aged mice after myocardial ischemia. Hum Gene Ther 2012 0.79
52 Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways. Virol J 2013 0.78
53 Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice. Mol Med 2010 0.78
54 Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. Mol Cancer Ther 2008 0.78
55 Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns. J Immunother 2016 0.77
56 Induction of human blood group a antigen expression on mouse cells, using lentiviral gene transduction. Hum Gene Ther 2010 0.77
57 The engineered thymidylate kinase (TMPK)/AZT enzyme-prodrug axis offers efficient bystander cell killing for suicide gene therapy of cancer. PLoS One 2013 0.77
58 Lentivirally transduced recipient-derived dendritic cells serve to ex vivo expand functional FcRgamma-sufficient double-negative regulatory T cells. Mol Ther 2007 0.76
59 IL-10 secretion increases signal persistence of HEMA-MMA-microencapsulated luciferase-modified CHO fibroblasts in mice. Tissue Eng Part A 2009 0.76
60 Functional expression of mouse relaxin and mouse relaxin-3 in the lung from an Ebola virus glycoprotein-pseudotyped lentivirus via tracheal delivery. Endocrinology 2006 0.76
61 Enhanced effect of vascular endothelial growth factor, thrombopoietin peptide agonist, SCF, and Flt3-L on LTC-IC and reporter gene transduction from umbilical cord blood CD34+ cells. Transfusion 2004 0.75
62 Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis. Methods Mol Biol 2015 0.75
63 Cloning, sequencing and characterization of lentiviral-mediated expression of rhesus macaque (Macaca mulatta) interleukin-2 receptor alpha cDNA. Dev Comp Immunol 2005 0.75
64 Implementation of high-throughput screening for Fabry disease in Toronto dialysis patients. NDT Plus 2008 0.75
65 Enhanced filter paper enzyme assay for high-throughput population screening for Fabry disease. Anal Biochem 2005 0.75
66 Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 production. Cancer Immunol Immunother 2010 0.75
67 Sequencing and characterization of the porcine α-galactosidase A gene: towards the generation of a porcine model for Fabry disease. Mol Biol Rep 2010 0.75